In an extremely odd case, a single 79-year-old patient was granted early access to Eli Lilly's powerful, still-experimental obesity drug retatrutide through the Food and Drug Administration's "compassionate use" program—raising immediate questions if that sole patient is President Donald Trump, according to a report by Stat News.

Lilly's retatrutide is a highly anticipated next-generation obesity drug that targets GIP and glucagon hormones in addition to GLP-1. It is currently in late-stage trials to treat obesity, diabetes, sleep apnea, and other conditions. Data from a Phase 3 trial that Lilly released in May indicates that patients with obesity (but without diabetes) who took the drug for 80 weeks lost 28 percent of their weight, an amount comparable to bariatric surgery.

Millions of Americans with obesity are eager to get the drug, with options being limited so far to enrolling in a clinical trial or trying to obtain it by dodgy methods.

Read full article

Comments

SpaceX will acquire AI coding tool Cursor for $60 billion in an all-stock transaction, the companies announced today. The deal is expected to close in the third quarter.

It comes just two days after SpaceX's unprecedented IPO and a few months after the merger of SpaceX and xAI, which brought a significant restructuring of xAI.

Cursor was one of the first tools to fully bake features that leverage large language models into an IDE. It's a branch of Visual Studio Code with heavy AI integration. However, incumbent platforms and bigger AI companies have since rolled out comparable features.

Read full article

Comments

Last year, a 24-year-old Canadian woman was in a mental health crisis and turned to ChatGPT for help. Hours later, that woman, Alice Carrier, took her own life.

According to a new lawsuit filed Thursday in San Francisco Superior Court and brought by Carrier’s surviving family, her ChatGPT session “encouraged Alice to kill herself.”

This lawsuit, like numerous other similar cases that have come before it, alleges a design defect with ChatGPT itself and blames OpenAI for knowingly deploying a dangerous product.

Read full article

Comments